美国 · SEC FORM 4
Spyre Therapeutics, Inc.
SYRE · Nasdaq · CIK 0001636282 · Healthcare · Biotechnology
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
94 同一窗口内观察到的 Form 4 交易行
78 sales · 16 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2022-08-25 · Souza Marcio · $50.4K
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出High
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
Burrows Scott LChief Financial Officer
○▼○▼○▼○▼○▼○▼▼○▼○▼
Sloan SheldonChief Medical Officer
○▼○▼○▼
Turtle CameronChief Executive Officer
▼▼▼▼▼▼
King-Jones HeidySee Remarks
○▼○▼○▼
Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak TomasDirector
○▼
HENDERSON MICHAEL THOMASDirector
▼▼
● 买入▼ 卖出○ 其他
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2022-08-25 · Souza Marcio.
近期 Form 4 活动
0买入
96卖出
20其他 Form 4 交易行
32SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出78 sale line(s) · 仅供背景
其他16 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 12,844,608
- 上期报告
- 12,129,443
- 日均成交量
- 1,444,056
- 回补天数
- 8.9
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2022-08-25 | Souza Marcio | 买入 (P) | Common Stock | 90,000 | USD 0.56 | USD 50,400 | SEC 申报 ↗ |
| 2022-06-08 | Hanley Jr. Michael Conick | 买入 (P) | Common Stock | 28,200 | USD 0.71 | USD 20,022 | SEC 申报 ↗ |
| 2022-03-16 | Quinn Anthony G. | 买入 (P) | Common Stock | 80,079 | USD 2.34 | USD 187,385 | SEC 申报 ↗ |
| 2022-03-15 | Quinn Anthony G. | 买入 (P) | Common Stock | 42,417 | USD 1.86 | USD 78,896 | SEC 申报 ↗ |
| 2022-03-14 | Quinn Anthony G. | 买入 (P) | Common Stock | 67,472 | USD 1.93 | USD 130,221 | SEC 申报 ↗ |
| 2022-03-11 | Quinn Anthony G. | 买入 (P) | Common Stock | 34,777 | USD 2.06 | USD 71,641 | SEC 申报 ↗ |
| 2022-03-11 | Alspaugh Jonathan | 买入 (P) | Common Stock | 75,000 | USD 2.08 | USD 156,000 | SEC 申报 ↗ |
| 2021-12-13 | Shanafelt Armen | 买入 (P) | Common Stock | 14,685 | USD 3.65 | USD 53,600 | SEC 申报 ↗ |
| 2021-12-10 | Shanafelt Armen | 买入 (P) | Common Stock | 13,516 | USD 3.65 | USD 49,333 | SEC 申报 ↗ |
| 2021-12-10 | Quinn Anthony G. | 买入 (P) | Common Stock | 10,526 | USD 3.75 | USD 39,472 | SEC 申报 ↗ |
| 2021-12-09 | Shanafelt Armen | 买入 (P) | Common Stock | 121,799 | USD 3.67 | USD 447,002 | SEC 申报 ↗ |
| 2021-12-09 | Quinn Anthony G. | 买入 (P) | Common Stock | 43,108 | USD 3.70 | USD 159,500 | SEC 申报 ↗ |
| 2021-12-09 | Alspaugh Jonathan | 买入 (P) | Common Stock | 50,000 | USD 3.72 | USD 186,000 | SEC 申报 ↗ |
| 2021-08-18 | Alspaugh Jonathan | 买入 (P) | Common Stock | 7,200 | USD 6.72 | USD 48,384 | SEC 申报 ↗ |
| 2021-08-17 | Alspaugh Jonathan | 买入 (P) | Common Stock | 23,392 | USD 6.50 | USD 152,048 | SEC 申报 ↗ |
Form 4 申报证据
116 transaction lines in the latest 365-day window; 149 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Turtle Cameron | 卖出 (S) | Common Stock | 15,000 | USD 92.01 | USD 1,380,105 | SEC 申报 ↗ |
| 2026-10-01 | King-Jones Heidy | 卖出 (S) | Common Stock | 28,933 | USD 91.03 | USD 2,633,902 | SEC 申报 ↗ |
| 2026-10-01 | King-Jones Heidy | 期权行权／转换 (M) | Common Stock | 28,933 | USD 14.50 | USD 419,528 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Turtle Cameron | 卖出 (S) | Common Stock | 15,000 | USD 92.01 | USD 1,380,105 | SEC 申报 ↗ |
| 2026-10-01 | King-Jones Heidy | 卖出 (S) | Common Stock | 28,933 | USD 91.03 | USD 2,633,902 | SEC 申报 ↗ |
| 2026-10-01 | King-Jones Heidy | 期权行权／转换 (M) | Common Stock | 28,933 | USD 14.50 | USD 419,528 | SEC 申报 ↗ |
| 2026-10-01 | Burrows Scott L | 卖出 (S) | Common Stock | 7,500 | USD 91.83 | USD 688,756 | SEC 申报 ↗ |
| 2026-10-01 | Burrows Scott L | 期权行权／转换 (M) | Common Stock | 7,500 | USD 14.50 | USD 108,750 | SEC 申报 ↗ |
| 2026-09-30 | Burrows Scott L | 卖出 (S) | Common Stock | 17,500 | USD 89.89 | USD 1,573,075 | SEC 申报 ↗ |
| 2026-09-30 | Burrows Scott L | 期权行权／转换 (M) | Common Stock | 17,500 | USD 14.50 | USD 253,750 | SEC 申报 ↗ |
| 2026-09-02 | King-Jones Heidy | 卖出 (S) | Common Stock | 400 | USD 90.00 | USD 36,000 | SEC 申报 ↗ |
| 2026-09-02 | King-Jones Heidy | 期权行权／转换 (M) | Common Stock | 400 | USD 14.50 | USD 5,800 | SEC 申报 ↗ |
| 2026-09-02 | Burrows Scott L | 卖出 (S) | Common Stock | 18,232 | USD 89.35 | USD 1,629,029 | SEC 申报 ↗ |
| 2026-09-01 | Turtle Cameron | 卖出 (S) | Common Stock | 15,000 | USD 87.29 | USD 1,309,410 | SEC 申报 ↗ |
| 2026-09-01 | King-Jones Heidy | 卖出 (S) | Common Stock | 27,999 | USD 87.31 | USD 2,444,529 | SEC 申报 ↗ |
| 2026-09-01 | King-Jones Heidy | 期权行权／转换 (M) | Common Stock | 27,999 | USD 14.50 | USD 405,986 | SEC 申报 ↗ |
| 2026-09-01 | Burrows Scott L | 卖出 (S) | Common Stock | 7,500 | USD 87.31 | USD 654,792 | SEC 申报 ↗ |
| 2026-09-01 | Burrows Scott L | 期权行权／转换 (M) | Common Stock | 7,500 | USD 14.50 | USD 108,750 | SEC 申报 ↗ |
| 2026-08-07 | Albers Jeffrey W. | 卖出 (S) | Common Stock | 23,000 | USD 104.53 | USD 2,404,190 | SEC 申报 ↗ |
| 2026-08-07 | Albers Jeffrey W. | 期权行权／转换 (M) | Common Stock | 5,000 | USD 10.39 | USD 51,950 | SEC 申报 ↗ |
| 2026-08-03 | Turtle Cameron | 卖出 (S) | Common Stock | 15,000 | USD 95.51 | USD 1,432,705 | SEC 申报 ↗ |
| 2026-08-03 | Burrows Scott L | 卖出 (S) | Common Stock | 7,500 | USD 95.57 | USD 716,771 | SEC 申报 ↗ |
| 2026-08-03 | Burrows Scott L | 期权行权／转换 (M) | Common Stock | 7,500 | USD 14.50 | USD 108,750 | SEC 申报 ↗ |
| 2026-07-01 | Turtle Cameron | 卖出 (S) | Common Stock | 15,000 | USD 87.69 | USD 1,315,346 | SEC 申报 ↗ |
| 2026-07-01 | Sloan Sheldon | 卖出 (S) | Common Stock | 8,334 | USD 87.70 | USD 730,896 | SEC 申报 ↗ |
| 2026-07-01 | Sloan Sheldon | 期权行权／转换 (M) | Common Stock | 8,334 | USD 27.46 | USD 228,852 | SEC 申报 ↗ |
| 2026-07-01 | Burrows Scott L | 卖出 (S) | Common Stock | 7,500 | USD 87.74 | USD 658,040 | SEC 申报 ↗ |
| 2026-07-01 | Burrows Scott L | 期权行权／转换 (M) | Common Stock | 7,500 | USD 14.50 | USD 108,750 | SEC 申报 ↗ |
| 2026-06-25 | Burrows Scott L | 卖出 (S) | Common Stock | 15,000 | USD 87.13 | USD 1,307,000 | SEC 申报 ↗ |
| 2026-06-25 | Burrows Scott L | 期权行权／转换 (M) | Common Stock | 15,000 | USD 14.50 | USD 217,500 | SEC 申报 ↗ |
| 2026-06-23 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas | 卖出 (S) | Common Stock | 4,684,781 | USD 85.31 | USD 399,658,667 | SEC 申报 ↗ |
| 2026-06-23 | Fairmount Funds Management LLC; Fairmount Healthcare Fund II L.P.; Harwin Peter Evan; Kiselak Tomas | C (C) | Common Stock | 666,680 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | 卖出 (S) | Common Stock | 20,000 | USD 100.00 | USD 2,000,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | SYRE |
| CIK | 0001636282 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 149 transaction lines from 2020-04-30 to 2026-10-01 17 P purchase lines · 100 S sale lines · 32 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.